Brief: Kintor's COVID-19 Trials For Proxalutamide To Expand Patient Enrolment
29/10/2020 13:52
Oct 29 (Reuters) - Kintor Pharmaceutical Ltd 9939.HK :
* KINTOR PHARMACEUTICAL'S COVID-19 CLINICAL TRIALS FOR
PROXALUTAMIDE TO EXPAND PATIENT ENROLMENT
* KINTOR PHARMACEUTICAL LTD - CLINICAL TRIAL OF ITS
ANTI-ANDROGEN
TREATMENT PROXALUTAMIDE DEMONSTRATED A POSITIVE TREND
* KINTOR PHARMACEUTICAL LTD - TO DATE, NO
MEDICAL-RELATED/DRUG-RELATED ADVERSE EVENTS (AES) HAVE BEEN
OBSERVED IN ANY OF THREE ARMS IN TRIAL
Source text for Eikon: ID:nPre647MDa
Further company coverage: 9939.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kintor Pharmaceutical
See all newsBrief: Kintor Pharmaceutical Receives Invention Patent Grant For KT-939 In China
Brief: Kintor Pharmaceutical Says Ming Ming Cheung Resigns As CFO
Brief: Kintor Pharmaceutical Says CEO Via Wholly Owned Co Increases Shareholding By 2.51 Million Shares
Brief: Kintor Pharmaceutical Says YTD 2026 Sales Revenue At RMB34 Million
Brief: Kintor Pharmaceutical Says Pharma's Kx-826 Phase Iii Trial In China Reaches Primary Endpoint